Past Issue

Volume 13, Number 3, Oct-Dec 2019 Pages: 225-229

Effects of Melatonin Administration on Chemical Pregnancy Rates of Polycystic Ovary Syndrome Patients Undergoing Intrauterine Insemination: A Randomized Clinical Trial

Fataneh Mokhtari, M.D, 1, Firouzeh Akbari Asbagh, M.D, 1, Ozra Azmoodeh, M.D, 1, *, Mahmood Bakhtiyari, Ph.D, 2, 3, Amir Almasi-Hashiani, Ph.D, 4,
Department of Obstetrics and Gynecology, IVF Unit, Yas Hospital, Tehran University of Medical Sciences, Tehran, Iran
Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran
Department of Community Medicine, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran
Department of Epidemiology and Reproductive Health, Reproductive Epidemiology Research Center, Royan Institute for Reproduc- tive Biomedicine, ACECR, Tehran, Iran
*Corresponding Address: P.O.Box: 1598718311 Department of Obstetrics and Gy- necology IVF Unit Yas Hospital Tehran University of Medical Sciences Tehran Iran



Oxidative stress as a potential cause of poor oocyte quality can influence a female’s reproductive system. This study aimed to investigate the effects of melatonin on chemical pregnancy rates of a significant number of polycystic ovary syndrome (PCOS) patients undergoing intrauterine insemination (IUI).

Materials and Methods

In this double-blinded randomized clinical trial (RCT) study, the samples included 198 PCOS patients fulfilling the inclusion criteria and undergoing the IUI treatment. On the third day of menstruation, a 3-mg melatonin tablet or its placebo was given to the patients according to the randomized study protocol; this prescription was continued until the day of human chorionic gonadotropin (hCG) administration. The current study attempted primarily to scrutinize the effect of melatonin administration on the rate of chemical pregnancy and mature follicles during the IUI treatment cycle, and secondarily to determine the endometrial thickness (ET) on the day of IUI.


The mean age of the participants in the study was 28.9 ± 5.5 years. The chemical pregnancy rate in the group receiving melatonin was about 32%, when it was 18% in the control group (P=0.012). Furthermore, it was concluded that the addition of melatonin to the treatment cycle of PCOS individuals could significantly improve the ET after the treatment (P<0.001).


The results of this study demonstrated that the treatment of PCOS patients undergoing IUI with mela- tonin significantly improves the rate of chemical pregnancy (Registration number: IRCT2017021132489N1).